Lead Product(s): FLT190
Therapeutic Area: Genetic Disease Product Name: FLT190
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2021
FLT190 is an investigational AAV gene therapy in development as a potential treatment for patients with Fabry disease. Dosing the second patient in the MARVEL-1 study is an important milestone for Freeline and evidence of progress in our Fabry program.